Peptide Capsules
Orforglipron Capsules
Orforglipron (LY3502970) is a small-molecule, non-peptide GLP-1 receptor agonist designed for oral administration in study models. 6 mg per capsule, 60 capsules
Identity & storage
- CAS number
- 2212020-52-3
- Molecular weight
- ≈883.0 g/mol
- Storage
- Keep the bottle tightly closed in a cool, dry place, protected from heat, moisture and direct light. Follow the storage and expiry instructions on the product label.
✓ In stock and ready to ship
Certificate of analysis View available reports and lot details
Orforglipron 6mg
Product identification & intended use
SKU: RB-CAPS-Orforglipron-6MG
For laboratory research use only. Not for human or veterinary use.
Description
Orforglipron (LY3502970) is an investigational GLP-1 receptor agonist that is a small molecule rather than a peptide, which is why it can be studied in oral form without the special absorption enhancers peptide pills need. Resolve BioLabs supplies orforglipron as 6 mg capsules, 60 per bottle.
What is Orforglipron?
Orforglipron was discovered by Chugai Pharmaceutical and licensed to Eli Lilly. Every approved GLP-1 agonist to date has been a peptide; orforglipron activates the same receptor with a non-peptide structure, which makes it stable in the gut and removes food and water restrictions associated with oral peptide formulations. It is in late-stage clinical development (the ACHIEVE and ATTAIN programs) and is not FDA approved.
Orforglipron specifications
| Research code | LY3502970 (also OWL833) |
|---|---|
| Compound type | Small molecule — non-peptide GLP-1 receptor agonist |
| Molecular formula | C48H48F2N10O5 |
| Molecular weight | ≈883.0 g/mol |
| Receptor target | GLP-1 receptor |
| Labeled content | 6 mg per capsule |
| Count | 60 capsules |
| Catalog reference | RB-CAPS-Orforglipron-6MG |
Research background
A Phase 2 obesity study of orforglipron was published in the New England Journal of Medicine in 2023 (Wharton et al.), and Phase 3 results have since been reported by Lilly. Research interest focuses on how a non-peptide agonist engages the GLP-1 receptor (it binds a different pocket than peptide agonists and shows biased signalling), and on comparisons with injectable incretin compounds such as GLP-3.
Format, storage and handling
Keep the bottle tightly closed in a cool, dry place, protected from heat, moisture and direct light. Follow the storage and expiry instructions on the product label.
Testing and documentation
Available reports describe the samples tested. Match the compound, format, strength and lot identifier with your supplied label; a supplier report does not by itself verify current stock. See the report library.
Related research compounds
Compare with GLP-3 (GIP/GLP-1/glucagon triple agonist) and tesofensine. Browse all research capsules.
Orforglipron FAQ
Is orforglipron a peptide?
No. It is a small molecule that activates the GLP-1 receptor, which is why it is suited to oral formulations.
How is orforglipron different from oral peptide GLP-1 agonists?
Oral peptide GLP-1 agonists need an absorption enhancer and fasting conditions; orforglipron is a non-peptide and does not.
Is orforglipron approved?
Not at the time of writing. It is sold here for laboratory research only.
For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement, and not intended to diagnose, treat, cure or prevent any disease.
